The First Clinical College of Nanjing Medical University, Nanjing, China ; Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, China.
PLoS One. 2013 Sep 16;8(9):e73671. doi: 10.1371/journal.pone.0073671. eCollection 2013.
Evidence suggest that IL-18 gene polymorphisms may be risk factors for several cancers. Increasing studies investigating the association between IL-18 gene promoter polymorphisms (-607 C>A and -137G>C) and cancer risk have yielded conflicting results.
METHODOLOGY/PRINCIPAL FINDINGS: We performed a meta-analysis of 26 studies including 4096 cases and 5222 controls. We assessed the strength of the association of IL-18 gene promoter -607 C>A and -137G>C polymorphisms with cancer risk and performed sub-group analyses by cancer types, ethnicities, source of controls and sample size. The pooled results revealed a significant increased risk of cancer susceptibility for -607 C>A (CA vs. CC: OR = 1.19, 95%CI: 1.04, 1.37, Pheterogeneity = 0.033; CA/AA vs. CC: OR = 1.17, 95% CI: 1.01, 1.34, Pheterogeneity = 0.007), but no significant association for -137 G>C was observed with overall cancer risk. Sub-group analyses revealed that an increased risk of nasopharyngeal carcinoma was both found for -607 C>A (CA/AA vs. CC: OR = 1.32, 95% CI: 1.04, 1.69, Pheterogeneity = 0.823) and -137G>C (GC/CC vs. GG: OR = 1.57, 95%CI: 1.26, 1.96, Pheterogeneity = 0.373). Consistent with the results of the genotyping analyses, the -607A/-137C and -607C/-137C haplotypes were associated with a significantly increased risk of nasopharyngeal carcinoma as compared with the -607C/-137G haplotype (-607A/-137C vs. -607C/-137G: OR = 1.26, 95%CI: 1.13, 1.40; Pheterogeneity = 0.569; -607C/-137C vs. -607C/-137G: OR = 1.14, 95%CI: 1.03, 1.27; Pheterogeneity = 0.775). As for gastrointestinal cancer, we also found that -607 C>A polymorphism was significantly associated with increased cancer risk (CA/AA vs. CC: OR = 1.25, 95% CI: 1.05, 1.50, Pheterogeneity = 0.458). Further sub-group analysis revealed that -137G>C polymorphism contributed to cancer risk in Asians but not in Caucasians (GC/CC vs. GG: OR = 1.31, 95%CI: 1.05, 1.64, Pheterogeneity<0.001).
The meta-analysis results suggest that IL-18 gene promoter -607 C>A polymorphism is significantly associated with overall cancer risk, especially in nasopharyngeal carcinoma and gastrointestinal cancer; and the -137 G>C polymorphism is associated with increased overall cancer risk in Asian populations and also significantly increases the risk of nasopharyngeal carcinoma.
有证据表明,IL-18 基因多态性可能是多种癌症的风险因素。越来越多的研究表明,IL-18 基因启动子多态性(-607C>A 和-137G>C)与癌症风险之间存在关联,但结果相互矛盾。
方法/主要发现:我们对包括 4096 例病例和 5222 例对照的 26 项研究进行了荟萃分析。我们评估了 IL-18 基因启动子-607C>A 和-137G>C 多态性与癌症风险之间的关联强度,并按癌症类型、种族、对照来源和样本量进行了亚组分析。汇总结果显示,-607C>A(CA 与 CC:OR=1.19,95%CI:1.04,1.37,P 异质性=0.033;CA/AA 与 CC:OR=1.17,95%CI:1.01,1.34,P 异质性=0.007)与癌症易感性显著相关,但总体癌症风险与-137G>C 无显著相关性。亚组分析显示,-607C>A(CA/AA 与 CC:OR=1.32,95%CI:1.04,1.69,P 异质性=0.823)和-137G>C(GC/CC 与 GG:OR=1.57,95%CI:1.26,1.96,P 异质性=0.373)与鼻咽癌风险增加均相关。与基因分型分析结果一致,-607A/-137C 和-607C/-137C 单倍型与鼻咽癌风险显著增加相关,而-607C/-137G 单倍型则不相关(-607A/-137C 与-607C/-137G:OR=1.26,95%CI:1.13,1.40;P 异质性=0.569;-607C/-137C 与-607C/-137G:OR=1.14,95%CI:1.03,1.27;P 异质性=0.775)。至于胃肠道癌症,我们还发现-607C>A 多态性与癌症风险增加显著相关(CA/AA 与 CC:OR=1.25,95%CI:1.05,1.50,P 异质性=0.458)。进一步的亚组分析显示,-137G>C 多态性在亚洲人群中与癌症风险相关,但在白种人群中不相关(GC/CC 与 GG:OR=1.31,95%CI:1.05,1.64,P 异质性<0.001)。
荟萃分析结果表明,IL-18 基因启动子-607C>A 多态性与总体癌症风险显著相关,特别是在鼻咽癌和胃肠道癌症中;-137G>C 多态性与亚洲人群总体癌症风险增加相关,也显著增加了鼻咽癌的风险。